Haier Pharmaceutical

Qingdao Guoxin Pharmaceutical Co., Ltd. — * Marine Drug and Chiral Drug R&D and Production Base Qingdao Guoxin Pharmaceutical Co., Ltd., established in 1994, is the first enterprise in China to produce marine drugs and the first enterprise in China to produce high-activity vitamin D drugs. The first marine drug in China, Alginic Acid Diester Sodium Tablets, was born in our company, which is the fifth marine drug recognized by the international academic and medical communities, and has won 24 international and domestic awards. In the active vitamin D market, Calcitriol Soft Capsules have ranked first in national market share for five consecutive years and second globally for three consecutive years. Since 2008, the company has paid over 900 million RMB in taxes cumulatively, including 166 million RMB in 2017, contributing 325,000 RMB per capita in tax revenue; the company's sales revenue has a compound annual growth rate of 21%, with key products achieving a compound annual growth rate of 42%, far exceeding the average level of the domestic pharmaceutical industry. The company has been recognized as the National Marine Drug Pilot Base, National Key High-tech Enterprise, Shandong Province Enterprise Technology Center, Qingdao Chiral Drug Development Engineering Technology Center, and the most valuable investment enterprise in China's pharmaceutical industry. The company's R&D products have become the leading brand in the marine drug industry due to their unique marine drug advantages and high-quality standards; three of the seven marine drugs marketed in China were developed by our company. The company has over 20 ongoing research projects, all of which are innovative or fill domestic gaps. To strengthen marine drug research and development and create a top-level marine drug R&D platform, the company has established deep cooperation with the School of Medicine and Pharmacy of Ocean University of China and the team of Academician Guan Huashi at Qingdao Marine Biomedical Research Institute, investing no less than 20 million RMB annually to promote the development of new marine Class I drugs and marine functional foods. The company has jointly established the China Bone Metabolic Disease Prevention and Treatment Alliance with China-Japan Friendship Hospital, setting up a special fund for the prevention and treatment of bone metabolic diseases with an annual investment of 20 million RMB. The first phase of the company's 80,000 square meter production base has been completed and put into operation, featuring world-class facilities and advanced production and testing equipment from leading global brands, utilizing internationally advanced industrial software systems to achieve intelligent monitoring and management throughout the entire production process. Guoxin Pharmaceutical will uphold the corporate philosophy of health, happiness, and longevity, with pioneering and adventurous spirit, and a cautious and prudent mindset, to courageously develop drugs in the fields of marine and osteoporosis, improving national health. Innovation is always on the road; the company will specialize, strengthen, and expand in the fields of marine drugs and osteoporosis, striving to become a world leader.